Esperion Therapeutics - Ann Arbor Competitors, Revenue, Alternatives and Pricing

Claim your profile


Detroit, MI USA
Total Funding:$22.8M
Lead Investor(s):Credit Suisse Securities (USA)

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Esperion Therapeutics - Ann Arbor's estimated annual revenue is currently $93.3M per year.
  • Esperion Therapeutics - Ann Arbor received $151.9M in venture funding in August 2017.
  • Esperion Therapeutics - Ann Arbor's estimated revenue per employee is $201,000
  • Esperion Therapeutics - Ann Arbor's total funding is $22.8M.

Employee Data

  • Esperion Therapeutics - Ann Arbor has 464 Employees.
  • Esperion Therapeutics - Ann Arbor grew their employee count by 229% last year.
  • Esperion Therapeutics - Ann Arbor currently has 10 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Frank W. Kerr C...
QST Consultatio...
Ash Stevens, a ...
Imperial Clinic...
Esperion Therap...
Gage Cannabis U...
Missing a competitor? Contribute!?

Esperion is the Lipid Management Company passionately committed to developing and commercializing convenient, complementary, consistent, once-daily, oral therapies for the treatment of patients with elevated LDL-C. Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering therapies that will make a substantial impact on reducing global cardiovascular disease; the leading cause of death around the world. The Company has two late-stage therapies in development; both with confirmed regulatory pathways to approval and defined global pivotal Phase 3 clinical development plans. Bempedoic acid and the Company's lead product candidate, the bempedoic acid / ezetimibe combination pill, are targeted therapies that have been shown to significantly reduce elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. Phase 1 and 2 studies conducted previously in more than 800 patients treated with bempedoic acid have produced clinically relevant LDL-C lowering results of up to 30 percent as monotherapy, approximately 50 percent in combination with ezetimibe, 64% when added-on to atorvastatin 20 mg, and an incremental 20+ percent when added to stable statin therapy. The Company has two Phase 3 products in development: 1) the once-daily, oral fixed dose bempedoic acid / ezetimibe combination pill, and 2) bempedoic acid (monotherapy) a once-daily, oral pill. For more information, please visit



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







Executive Contacts

Regina Gore CavaliereChief Ethics and Compliance OfficerEmail Available
Tim MaylebenCEO/PresidentEmail Available
Marianne AndreachSenior Vice President, Product PlanningEmail Available
Pragna PatelDirector Clinical OperationsEmail Available
Jo WellsDirector, Clinical Quality AssuranceEmail Available
Eric JozefiakSenior DirectorEmail Available
Jeanne BrittainAssociate Director of ProjectEmail Available
Heather PershAssociate Director, Human ResourcesEmail Available
Matt BigertSenior Director - Analytical Research and DevelopmentEmail Available
Kimberly StranickVice President

Esperion Therapeutics - Ann Arbor News

09/03/2019 - Esperion To Grant 75,000 Shares To 18 New Employees

ANN ARBOR—Esperion Therapeutics Inc., a developer of a new class of cholesterol-reducing drugs, announced that the compensation ...

09/08/2019 - Esperion Completes Patient Enrollment in the Global CLEAR ...

ANN ARBOR, Mich., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the completion of patient enrollment ...

09/03/2019 - Esperion Provides Bempedoic Acid Franchise Development ...

ANN ARBOR, Mich., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development ...

Esperion Therapeutics - Ann Arbor Funding

DateAmountRoundLead InvestorsReference
2003-08-01$64.0MPublic OfferingArticle
2013-04-26$33.0MUndisclosedLongitude CapitalArticle
2015-03-19$172.5MUndisclosedCredit Suisse Securities (USA)Article

Esperion Therapeutics - Ann Arbor Executive Hires

2002-07-17William BrinkerhoffVP Business DevelopmentArticle
2003-06-06Adeoye OlukotunSVP Clinical/Reg Aff/CMOArticle
2012-04-10Noah RosenbergChief Medical OfficerArticle
2013-01-07Tim MaylebenPresident/CEOArticle
2014-01-14Antonio M. GottoDirectorArticle

Esperion Therapeutics - Ann Arbor Acquisitions

DateCompany NameAmountNotesReference